2. Search Result
Search Result
Results for "

Amyloidosis

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

6

Inhibitory Antibodies

2

Natural
Products

3

Antibodies

12

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103157
    PD146176
    Maximum Cited Publications
    6 Publications Verification

    NSC168807

    		 Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176
  • HY-132609
    Patisiran sodium
    1 Publications Verification

    		 Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis .
    Patisiran sodium
  • HY-132589
    Vutrisiran
    2 Publications Verification

    ALN-TTRsc02

    		 Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research .
    Vutrisiran
  • HY-113283
    Homogentisic acid

    		Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin Neurological Disease Metabolic Disease Cancer
    Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
    Homogentisic acid
  • HY-132608
    Inotersen sodium

    ISIS-420915 sodium

    		 Transthyretin (TTR) Neurological Disease
    Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy .
    Inotersen sodium
  • HY-112974
    Inotersen

    GSK-2998728; ISIS-420915

    		 Transthyretin (TTR) Cardiovascular Disease Neurological Disease
    Inotersen (GSK-2998728; ISIS-420915) is a 2'-O-methoxyethyl-modified antisense oligonucleotide and transthyretin (TTR) inhibitor with low genotoxicity. Inotersen triggers RNase H1-mediated degradation by binding to TTR mRNA, thereby effectively reducing the production of both mutant and wild-type transthyretin in the liver. Inotersen significantly reduces amyloid fiber deposition, yet specific toxicities such as inflammation or tumors are observed at high doses in some animal models. Inotersen is used in studies of hereditary transthyretin amyloidosis and the associated polyneuropathy and cardiomyopathy .
    Inotersen
  • HY-148089
    Eplontersen
    1 Publications Verification

    		 Transthyretin (TTR) Neurological Disease
    Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .
    Eplontersen
  • HY-P2358
    PSMα3

    		NF-κB p38 MAPK Infection Inflammation/Immunology
    PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .
    PSMα3
  • HY-P99481
    Birtamimab

    NEOD001

    		 Amyloid-β Neurological Disease
    Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
    Birtamimab
  • HY-P991128
    Cliramitug

    NI-006; ALXN2220

    		 Transthyretin (TTR) Cardiovascular Disease Neurological Disease
    Cliramitug (NI-006; ALXN2220) is a monoclonal antibody that targets human transthyretin (TTR). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases .
    Cliramitug
  • HY-109165A
    Acoramidis hydrochloride

    AG10 hydrochloride

    		 Transthyretin (TTR) Metabolic Disease Endocrinology
    Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis .
    Acoramidis hydrochloride
  • HY-109165
    Acoramidis

    AG10

    		 Transthyretin (TTR) Metabolic Disease Endocrinology
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis .
    Acoramidis
  • HY-P99358
    Dezamizumab

    GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)

    		 Complement System Inflammation/Immunology
    Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis .
    Dezamizumab
  • HY-P990785
    Etentamig

    ABBV-383; TNB 383B

    		 CD3 Cardiovascular Disease Inflammation/Immunology Cancer
    Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
    Etentamig
  • HY-P99105
    Anselamimab

    CAEL-101

    		 Apolipoprotein Amyloid-β Neurological Disease
    Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
    Anselamimab
  • HY-132589A
    Vutrisiran sodium
    2 Publications Verification

    ALN-TTRsc02 sodium

    		 Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Vutrisiran sodium (ALN-TTRsc02 sodium) is a liver-directed small interfering RNA (siRNA). Vutrisiran sodium targets the mRNA of transthyretin (TTR), and is applicable to studies on transthyretin (TTR)-mediated amyloidosis .
    Vutrisiran sodium
  • HY-148089A
    Eplontersen sodium
    1 Publications Verification

    		 Transthyretin (TTR) Neurological Disease
    Eplontersen sodium the sodium salt form of Eplontersen (HY-148089). Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .
    Eplontersen sodium
  • HY-150151A
    GalNac-siRNA negative control (21nt)

    		LYTACs Cardiovascular Disease
    GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .
    GalNac-siRNA negative control (21nt)
  • HY-132590A
    Revusiran sodium

    ALN-TTRSC sodium

    		 Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis .
    Revusiran sodium
  • HY-128849
    Eprodisate (70% in water)

    		Amyloid-β Inflammation/Immunology
    Eprodisate (70% in water) is an amyloid inhibitor that interferes with the interaction between amyloidogenic proteins and glycosaminoglycans, thereby inhibiting the aggregation of amyloid fibrils and the deposition of fibrils in tissues. Eprodisate (70% in water) slows the progression of renal disease associated with AA amyloidosis and may be useful for other types of amyloidosis .
    Eprodisate (70% in water)
  • HY-B1141
    Eprodisate disodium

    NC-503

    		 Amyloid-β Others
    Eprodisate disodium (NC-503) is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.
    Eprodisate disodium
  • HY-153609
    AS-Patisiran sodium

    		Transthyretin (TTR) Small Interfering RNA (siRNA) Neurological Disease
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis .
    AS-Patisiran sodium
  • HY-132590
    Revusiran

    ALN-TTRSC

    		 Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Revusiran (ALN-TTRSC) is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran exhibits favorable nonclinical safety profiles. Revusiran can be used in studies related to transthyretin-mediated amyloidosis .
    Revusiran
  • HY-176518
    ssPalmE-P4-C2

    		Liposome Ser/Thr Protease Infection Neurological Disease Metabolic Disease
    ssPalmE-P4-C2 is a SS-cleavable and pH-sensitive lipid-like material (ssPalm) with a vitamin E‑scaffold. ssPalmE-P4-C2 improves gene knockdown activity against FVII with an ED50 of 0.5 mg/kg. ssPalmE-P4-C2 can be used to synthesize lipid nanoparticles (LNPs) for delivering siRNA to the hepatocyte. ssPalmE-P4-C2 can be used for the RNA therapies for dyslipidemia, hepatitis B/C infections and transthyretin amyloidosis research .
    ssPalmE-P4-C2
  • HY-19771
    GSK 3039294

    GSK294; amyloid P-IN-1

    		 Amyloid-β Cancer
    amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    GSK 3039294
  • HY-155299
    PITB

    		Transthyretin (TTR) Neurological Disease
    PITB is a selective and orally active transthyretin (TTR) aggregation inhibitor. PITB can be used for transthyretin amyloidosis (ATTR) disease research .
    PITB
  • HY-P991039
    Zamubafusp alfa

    AT-02

    		 Amyloid-β Inflammation/Immunology
    Zamubafusp alfa (AT-02) is an immunoglobulin-peptide fusion protein consisting of a humanized IgG1 and the pan-amyloid reactive peptide p5R. Zamubafusp alfa binds to two ubiquitous components of all amyloids, namely amyloid fibrils and highly sulfated heparan sulfate glycans. Zamubafusp alfa enhances macrophage phagocytosis for amyloid clearance and can be used in research related to systemic amyloidosis .
    Zamubafusp alfa
  • HY-W259888
    (R)-2-Hydroxysuccinic acid methyl ester

    		Biochemical Assay Reagents Neurological Disease Cancer
    (R)-2-Hydroxysuccinic acid methyl ester is a biochemical that can be used for the research of cancer or amyloidosis .
    (R)-2-Hydroxysuccinic acid methyl ester
  • HY-153417
    Anti-amyloid agent-1

    		Amyloid-β Neurological Disease
    Anti-amyloid agent-1 (ex1140) is a potent anti-amyloid compound and inhibits amyloid aggregation, provides a useful method for amyloidosis research .
    Anti-amyloid agent-1
  • HY-W355463
    3-Demethylthiocolchicine

    		Microtubule/Tubulin Neurological Disease Inflammation/Immunology Cancer
    3-Demethylthiocolchicine is a colchicine (HY-16569) analog with broad-spectrum antitumor activity. 3-Demethylthiocolchicine has the same effects and activities as colchicine in blocking casein-induced amyloidosis, microtubule binding, and anti-inflammatory effects, with significantly lower toxicity .
    3-Demethylthiocolchicine
  • HY-176233
    Transthyretin-IN-4

    		Transthyretin (TTR) Cardiovascular Disease
    Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC50: 0.09 µM, pIC50: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias .
    Transthyretin-IN-4
  • HY-103157R
    PD146176 (Standard)

    NSC168807 (Standard)

    		 Reference Standards Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176 (Standard)
  • HY-160612
    Transthyretin-IN-2

    		Transthyretin (TTR) Neurological Disease
    Transthyretin-IN-2 (Compound 36) is a transthyretin (TTR) amyloidsis inhibitor, with IC50 and pIC50 values of 1.31 μM and 5.88 μM. Transthyretin-IN-2 can be used for the research of TTR amyloidosis diseases .
    Transthyretin-IN-2
  • HY-161505
    Transthyretin-IN-3

    		Transthyretin (TTR) Others
    Transthyretin-IN-3 (compound 6) is a designed benzofuran analogue. Transthyretin-IN-3 selectively binds to plasma transthyretin (TTR) to inhibit Amyloid aggregation (IC50=5.0±0.2 μM). Transthyretin-IN-3 can bind to TTR's thyroxine binding site specifically by carrying chlorine substituents at specific locations in its structure. This binding can prevent TTR tetramers from dissociating into unstable monomers .
    Transthyretin-IN-3
  • HY-145343A
    (9R)-RO7185876

    		γ-secretase Amyloid-β Neurological Disease
    (9R)-RO7185876 (Compound example 16) is a γ-secretase inhibitor. (9R)-RO7185876 inhibits Αβ42 secretion. (9R)-RO7185876 can be used for the researches of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, multi-infarct dementia, dementia pugilistica or Down syndrome .
    (9R)-RO7185876
  • HY-P2358A
    PSMα3 TFA

    		NF-κB p38 MAPK Infection Inflammation/Immunology
    PSMα3 TFA is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 TFA forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 TFA forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 TFA is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .
    PSMα3 TFA
  • HY-185504
    Nexiguran

    		Others Others
    Nexiguran is one component of Nexiguran ziclumeran and also an sgRNA targeting the human TTR gene. Nexiguran ziclumeran (NTLA-2001) is a CRISPR gene-editing therapy that targets hepatic TTR, and it can also be used for research on transthyretin amyloidosis .
    Nexiguran
  • HY-P11698
    Guanidino-G-Clamp-PNA

    		DNA Alkylator/Crosslinker Transthyretin (TTR) Cancer
    Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis .
    Guanidino-G-Clamp-PNA
  • HY-183593
    SHIP1-IN-1

    		Phosphatase Akt Interleukin Related Neurological Disease
    SHIP1-IN-1 is an orally active, blood-brain barrier-permeable SHIP1 ligand. SHIP1-IN-1 exhibits IC50 values of 384 μM and 177 μM against human SHIP1, and an IC50 value of 379 μM against murine SHIP1. SHIP1-IN-1 alters the binding state of SHIP1 to phosphatidylinositol membranes, and regulates phosphoinositide pools and phosphorylated AKT levels. SHIP1-IN-1 enhances the uptake of myelin/membrane fragments and amyloid proteins by microglia, alters gene expression and reduces IL-1β levels. SHIP1-IN-1 can be used in studies related to Alzheimer's disease .
    SHIP1-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: